IPSEN (OTCMKTS:IPSEY) Sets New 12-Month High – Here’s What Happened

IPSEN (OTCMKTS:IPSEY) shares hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $39.78 and last traded at $39.78, with a volume of 226 shares changing hands. The stock had previously closed at $38.45.

Analyst Ratings Changes

A number of equities research analysts have commented on IPSEY shares. BNP Paribas Exane cut shares of IPSEN to an “underperform” rating in a report on Wednesday, November 26th. UBS Group downgraded IPSEN from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 8th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research note on Monday, November 3rd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

IPSEN Stock Up 1.8%

The firm has a 50 day moving average of $36.34 and a 200 day moving average of $34.38.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).